Visit the ACCC COVID-19 Resource Center & Discussion Group for Insights on Providing Optimal Patient Care During the Pandemic.
 

Share

    


Overview

As the role of immunotherapies in treating patients with renal cell carcinoma (RCC) grows, keeping up with the pace of emerging data on combination therapy regimens, effective practices for monitoring and managing immune-related adverse events, and educating patients to empower informed decision-making can be challenging.

This CME, CNE, and CPE-accredited educational program is designed to provide all members of the multidisciplinary care team knowledge and resources to successfully address practical issues and barriers faced in integration of immunotherapies into the treatment of renal cell carcinoma (RCC).

The program is being presented in two formats: a live, on-site learning workshop and an audio-guided online course.

Live Workshops

Three cancer programs have been selected to host live, half-day workshops onsite at their institutions. Programs participating in the on-site, live workshops are:

  • The Cancer Center at Christus St. Michael Health System
    Texarkana, Texas
  • OSF HealthCare Saint Anthony Medical Center
    Patricia D. Pepe Center for Cancer Care
    Rockford, Illinois
  • Hawaii Pacific Health
    Honolulu, Hawaii
At these live workshops, a three-member multidisciplinary expert faculty panel provides both didactic presentations and collaborative open discussion with members of the multidisciplinary care team. Topics covered include, but are not limited to, a review of the rationale for using immunotherapies and immunotherapy combinations, optimal sequencing of therapies, patient selection criteria, and monitoring and managing immune-related adverse events (irAEs) in patients with metastatic RCC. Collateral issues discussed include coordination and communication within the multidisciplinary care team, coverage and reimbursement, and fostering patient education and engagement.

Laura Wood, RN, MSN, OCN; Jocelyn Mohs, PharmD, BCOP; Timothy M. Kuzel, MD

Workshop Faculty Laura Wood, RN, MSN, OCN; Jocelyn Mohs, PharmD, BCOP; Timothy M. Kuzel, MD.

Paula Caryski, President,  OSF Health, Dr. Iftekhar Ahmad, Radiation Oncologist, and Thelma Baker, Director of Oncology

Paula Caryski, President, OSF HealthCare Saint Anthony Medical Center; Dr. Iftekhar Ahmad, Radiation Oncologist; Thelma Baker, Director of Oncology Services.

During the workshop, participants use the Institute for Healthcare Improvement's Plan-Do-Study-Act tool to develop a customized action plan.  Workshop sites will report on their progress at 3 and 6 months post-participation.

We recently hosted the ACCC live workshop, "The Evolving Immunotherapeutic Landscape in Renal Cell Carcinoma." What a great experience and such a valuable benefit of our ACCC Cancer Program Membership. The three-member multidisciplinary faculty were very knowledgeable. After their educational session, we met for a collaborative quality improvement workshop with the speakers and ACCC onsite staff. They helped us develop a plan to improve our Immuno-oncology management of patients. We will use this workshop to meet our 2020 CoC standard 7.3 (Quality Improvement Initiative).

Thelma Baker, MSN, RN, OCN, NEA-BC
Director of Oncology Services
OSF HealthCare Saint Anthony Medical Center

Online Course

This initiative aims to provide guidance to the multidisciplinary cancer care team on the practical issues and barriers associated with incorporating immunotherapies in the treatment of RCC in the community setting. This initiative will review the rationale for combining immunotherapies with an angiogenesis inhibitor, vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR TKI), optimal drug combinations, sequencing of therapies, patient selection criteria and monitoring and managing immune-related adverse events (irAEs) in patients with RCC.
Learn More & Register

Abstracts & Presentations

Jointly Provided By:

AXIS Medical Education Logo
accclogo_hires-300x78 

Supporter

This activity is supported by educational grants from Eisai, EMD Serono, and Pfizer.